Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, Villejuif, France.
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Oral Oncol. 2018 Jul;82:108-114. doi: 10.1016/j.oraloncology.2018.05.015. Epub 2018 May 21.
One of the major concerns in oncology lies in the ability to detect recurrences at their earliest stage to increase the likelihood of cure following second line, or salvage, therapy. Although human papillomavirus (HPV)-driven oropharyngeal cancers have a good prognosis, 20-25% of patients will recur within 5 years of treatment and a significant portion will die from their disease. In recent years, great effort has been put toward evaluating the potential clinical utility of HPV-related biomarkers for early diagnosis of recurrent disease. Indeed, following completion of treatment, detection of HPV-DNA in oral rinses or blood and serologic assays against HPV oncoproteins could be helpful to track residual disease or recurrence. Several recent studies have reported promising findings, thus potentially paving the way for the use of biomarkers in the management of HPV-OPC. In this review, we evaluate and discuss the current knowledge on this topic and provide some directions for future research.
肿瘤学中的一个主要关注点在于能否在最早阶段检测到复发，以提高二线或挽救性治疗后治愈的可能性。尽管 HPV 驱动的口咽癌预后良好，但仍有 20-25%的患者在治疗后 5 年内复发，其中很大一部分会死于疾病。近年来，人们致力于评估 HPV 相关生物标志物在早期诊断复发性疾病中的潜在临床应用价值。事实上，在治疗完成后，检测口腔冲洗液或血液中的 HPV-DNA 以及针对 HPV 致癌蛋白的血清学检测可能有助于追踪残留疾病或复发。最近的几项研究报告了有希望的结果，从而为 HPV-OPC 管理中生物标志物的使用铺平了道路。在这篇综述中，我们评估和讨论了这一主题的现有知识，并为未来的研究提供了一些方向。
